Khedmat Hossein, Amini Mohsen, Ghamar-Chehreh Mohammad Ebrahim, Agah Shahram
Baqiyatalah Research Center for Gastroenterology and Liver Disease, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Saudi J Kidney Dis Transpl. 2014 Jan;25(1):1-8. doi: 10.4103/1319-2442.124455.
Despite the introduction of strict hygienic precautions preventing infection spread of hepatitis C virus (HCV) in dialysis settings, this infection is still prevalent among dialysis patients due to procedures making the patients vulnerable to infection through blood contamination. Treatment of HCV infection in dialysis patients is also less successful than that in the non-uremic population due to contraindication of using ribavirin, a main drug, in the infected patients. In this review article we aim to investigate the feasibility of the current antiviral therapies in dialysis patients infected with HCV infection.
尽管在透析环境中采取了严格的卫生预防措施以防止丙型肝炎病毒（HCV）传播感染，但由于一些操作会使患者因血液污染而容易感染，这种感染在透析患者中仍然很普遍。由于感染患者禁用主要药物利巴韦林，透析患者的HCV感染治疗也比非尿毒症人群的治疗成功率低。在这篇综述文章中，我们旨在研究当前抗病毒疗法对感染HCV的透析患者的可行性。
